Detection and clinical importance of micrometastatic disease

Journal of the National Cancer Institute

Volumn 91, Issue 13, 1999, Pages 1113-1124

  Pantel, Klaus ^a   Cote, Richard J ^b   Fodstad, Øystein ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; CYTOKERATIN; EDRECOLOMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOTOXIN;

ADJUVANT THERAPY; ANGIOGENESIS; BONE MARROW METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CELL CYCLE G0 PHASE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOTHERAPY; LYMPH NODE METASTASIS; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; SYSTEMIC CIRCULATION; TUMOR CELL;

EID: 0033532955     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.13.1113     Document Type: Review

References (180)

1. Pantel K, Riethmuller G. Micrometastasis detection and treatment with monoclonal antibodies. Curr Top Microbiol Immunol 1996;213(Pt 3): 1-18.
2. Pantel K, Schlimok G, Braun S, Kutter D, Schaller G, Funke I, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85:1419-24.
3. Pantel K, Izbicki JR, Angstwurm M, Braun S, Passlick B, Karg O, et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 1993;53:1027-31.
4. Burkhardt R, Frisch B, Kettner G. The clinical study of micro-metastatic cancer by bone biopsy. Bull Cancer 1980;67:291-305.
5. Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H, et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A 1987;84:8672-6.
6. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749-56.
7. Cote RJ, Beattie EJ, Chaiwun B, Shi SR, Harvey J, Chen SC, et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 1995;222:415-23; discussion 423-5.
8. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997;278:1054-9.
9. Soeth E, Vogel I, Roder C, Juhl H, Marxsen J, Kruger U, et al. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res 1997;57:3106-10.
10. Wyld DK, Selby P, Perren TJ, Jonas SK, Allen-Mersh TG, Wheeldon J, et al. Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. Int J Cancer 1998;79:288-93.
11. Redding WH, Coombes RC, Monaghan P, Clink HM, Imrie SF, Dearnaley DP, et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983;2:1271-4.
12. Fodstad O, Overli GE, Hovland B, Andresen M, Olsen OE, Hoifodt HK. New method for phenotypic characterization of micrometastatic cancer cells [abstract]. Proc Am Assoc Cancer Res 1998;39:436 [abstract 2969].
13. Dearnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink HM, et al. Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer 1981; 44:85-90.
14. Beiske K, Myklebust AT, Aamdal S, Langholm R, Jakobsen E, Fodstad O. Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods. Am J Pathol 1992;141:531-8.
15. Porro G, Menard S, Tagliabue E, Orefice S, Salvadori B, Squicciarini P, et al. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients. Cancer 1988;61:2407-11.
16. Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996;347:649-53.
17. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996;88:1652-8.
18. Osborne MP, Rosen PP. Detection and management of bone marrow micrometastases in breast cancer. Oncology (Huntingt) 1994;8:25-31; discussion 35-6, 39-42.
19. Rye PD, Hoifodt HK, Overli GE, Fodstad O. Immunobead filtration: a novel approach for the isolation and propagation of tumor cells. Am J Pathol 1997;150:99-106.
20. Myklebust AT, Pharo A, Fodstad O. Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads. Br J Cancer 1993;67:1331-6.
21. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994;69:566-71.
22. Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Dearnaley D, et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 1991;27:1552-5.
23. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
24. Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science 1998;279:514-9.
25. Krismann M, Todt B, Schroder J, Gareis D, Muller KM, Seeber S, et al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995;13:2769-75.
26. Traweek ST, Liu J, Battifora H. Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction. Am J Pathol 1993;142: 1111-8.
27. Zippelius A, Kufer P, Honold G, Kollermann MW, Oberneder R, Schlimok G, et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997;15:2701-8.
28. Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998;16:2632-40.
29. Ruud P, Fodstad O, Hovig E. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells. Int J Cancer 1999;80:119-25.
30. Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3:165-73.
31. Braun S, Muller M, Hepp F, Schlimok G, Riethmuller G, Pantel K. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status [letter]. J Natl Cancer Inst 1998;90:1099-101.
32. Cote RJ, Rosen PP, Hakes TB, Sedira M, Bazinet M, Kinne DW, et al. Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease. Am J Surg Pathol 1988;12:333-40.
33. Chaiwun B, Saad AD, Groshen S, Chen SC, Mazumder A, Imam A, et al. Immunohistochemical detection of occult carcinoma in bone marrow and blood: critical analysis of efficiency of separation, preparation and limits of detection in a model system. Diagn Oncol 1992;2:267-76.
34. Osborne MP, Asina S, Wong GY, Old LJ, Cote RJ. Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: sensitivity in a model system. Cancer Res 1989;49:2510-3.
35. Naume B, Borgen E, Beiske K, Herstad TK, Ravnas G, Renolen A, et al. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 1997;6:103-14.
36. Martin VM, Siewert C, Scharl A, Harms T, Heinze R, Ohl S, et al. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. Exp Hematol 1998;26:252-64.
37. Naume B, Borgen E, Nesland JM, Beiske K, Gilen E, Renolen A, et al. Increased sensitivity for detection of micrometastases in bone-marrow/ peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer 1998;78:556-60.
38. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998;95:4589-94.
39. Paget S. The distribution of secondary growth in cancer of the breast. Lancet 1889;1:571-3.
40. International symposium. Critical determinants in cancer progression and metastasis. A centennial celebration of Dr. Stephen Paget's 'seed and soil' hypothesis. March 6-10, 1989, Houston, Texas. Abstracts. Cancer Metastasis Rev 1989;8:93-197.
41. Kjonniksen I, Breistol K, Fodstad O. Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin. Cancer Res 1992;52: 1347-51.
42. Dong Z, Radinsky R, Fan D, Tsan R, Bucana CD, Wilmanns C, et al. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 1994;86: 913-20.
43. Fodstad O, Kjonniksen I. Microenvironment revisited: time for reappraisal of some prevailing concepts of cancer metastasis. J Cell Biochem 1994;56:23-8.
44. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986;150:195-203.
45. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979;189:496-502.
46. Bonnheim DC, Petrelli NJ, Herrera L, Walsh D, Mittelman A. Osseus metastases from colorectal carcinoma. Am J Surg 1986;151:457-9.
47. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;340:685-9.
48. Jauch KW, Heiss MM, Gruetzner U, Funke I, Pantel K, Babic R, et al. Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 1996;14:1810-7.
49. Mansi JL, Berger U, Easton D, McDonnell T, Redding WH, Gazet JC, et al. Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J (Clin Res Ed) 1987;295:1093-6.
50. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 1998;16:557-66.
51. Fadlon EJ, Rees RC, McIntyre C, Sharrard RM, Lawry J, Hamdy FC. Detection of circulating prostate-specific antigen-positive cells in patients with prostate cancer by flow cytometry and reverse transcription polymerase chain reaction. Br J Cancer 1996;74:400-5.
52. Brandt B, Junker R, Griwatz C, Heidl S, Brinkmann O, Semjonow A, et al. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res 1996;56:4556-61.
53. Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, et al. Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 1998;185:427-34.
54. Denis MG, Tessier MH, Dreno B, Lustenberger P. Circulating micrometastases following oncological surgery [letter]. Lancet 1996;347:913.
55. Eschwege P, Dumas F, Blanchet P, Le Maire V, Benoit G, Jardin A, et al. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995;346:1528-30.
56. Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K. Tumor cells in blood shed from the surgical field. Arch Surg 1995;130: 387-93.
57. Weitz J, Kienle P, Lacroix J, Willeke F, Benner A, Lehnert T, et al. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res 1998;4:343-8.
58. Gusterson B, Ott R. Occult axillary lymph-node micrometastases in breast cancer [letter]. Lancet 1990;336:434-5.
59. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
60. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 1996;73:88-95.
61. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992;66:523-7.
62. Cote JR, Peterson HF, Chalwun B, Gelber RD, Goldhirsch R, Castiglione-Gertsch M, et al. The role of the immunohistochemical detection of lymph node metastases in the management of breast cancer. Lancet. In press 1999.
63. Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EW Jr. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994; 73:563-9.
64. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223-8.
65. Maehara Y, Oshiro T, Endo K, Baba H, Oda S, Ichiyoshi Y, et al. Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery 1996;119:397-402.
66. Passlick B, Izbicki JR, Kubuschok B, Nathrath W, Thetter O, Pichlmeier U, et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 1994;12:1827-32.
67. Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 1999;17:19-24.
68. Cote RJ, Hawes D, Chaiwun B, Beattie EJ Jr. Detection of occult metastases in lung carcinomas: progress and implications for lung cancer staging. J Surg Oncol 1998;69:265-74.
69. Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997;337:1188-94.
70. Freeman JA, Esrig D, Grossfeld GD, Stein JP, Chen SC, Young LL, et al. Incidence of occult lymph node metastases in pathological stage C (pT3NO) prostate cancer. J Urol 1995;154:474-8.
71. Edelstein RA, Zietman AL, de las Morenas A, Krane RJ, Babayan RK, Dallow KC, et al. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Urology 1996;47:370-5.
72. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am J Surg Pathol 1988;12:612-8.
73. Corey E, Corey MJ. Detection of disseminated prostate cells by reverse transcription-polymerase chain reaction (RT-PCR): technical and clinical aspects. Int J Cancer 1998;77:655-73.
74. Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review. J Surg Oncol 1998;67:194-202.
75. Taylor CR, Cote RJ. Immunohistochemical markers of prognostic value in surgical pathology. Histol Histopathol 1997;12:1039-55.
76. Hitchcock CL, Arnold MW, Young DC, Schneebaum S, Martin EW Jr. TAG-72 expression in lymph nodes and RIGS [letter]. Dis Colon Rectum 1996;39:473-5.
77. Bostick PJ, Hoon DS, Cote RJ. Detection of carcinoembryonic antigen messenger RNA in lymph nodes from patients with colorectal cancer [letter]. N Engl J Med 1998;339:1643-4.
78. Hayashi N, Ito I, Yanagisawa A, Kato Y, Nakamori S, Imaoka S, et al. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995;345:1257-9.
79. Ahrendt SA, Yang SC, Wu L, Westra WH, Jen J, Califano JA, et al. Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non-small cell lung cancer. Clin Cancer Res 1997;3:1207-14.
80. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:429-35.
81. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
82. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220: 391-8; discussion 398-401.
83. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-9; discussion 399-401.
84. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864-7.
85. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 1998;339:941-6.
86. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
87. Van der Velde-Zimmermann D, Roijers JF, Bouwens-Rombouts A, De Weger RA, De Graaf PW, Tilanus MG, et al. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 1996;149:759-64.
88. Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res 1998;58:4581-4.
89. Schwarz G. Cytomorphology and cell yield in a new cytocentrifugal technique allowing the collection of the cell-free supernatant. Lab Med 1991; 15:45-50.
90. Cote RJ, Shi SR, Beattie EJ, Makarewicz B, Chaiwun B. Automated detection of occult bone marrow micrometastases in patients with operable lung carcinoma [abstract]. Proc ASCO 1997;16:458a.
91. Makarewicz K, McDuffie L, Shi SR, Catterjee S, Yang C, Taylor C, et al. Immunohistochemical detection of occult micrometastases using an automated intelligent microscopy system [abstract]. Proc Am Assoc Cancer Res 1997;38:269 [abstract 1805].
92. Fodstad O, Trones GE, Forus A, Rye PD, Beiske K, Aamdal S, et al. Improved immunomagnetic method for detection and characterization of cancer cells in blood and bone marrow [abstract]. Proc Am Assoc Cancer Res 1997;38:26 [abstract 172].
93. Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res 1991;51:2706-9.
94. Molino A, Colombatti M, Bonetti F, Zardini M, Pasini F, Perini A, et al. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer 1991;67:1033-6.
95. Wingren S, Guerrieri C, Franlund B, Stal O. Loss of cytokeratins in breast cancer cells using multiparameter DNA flow cytometry is related to both cellular factors and preparation procedure. Anal Cell Pathol 1995;9: 229-33.
96. Vredenburgh JJ, Silva O, Tyer C, DeSombre K, Abou-Ghalia A, Cook M, et al. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother 1996;5:57-62.
97. Gross HJ, Verwer B, Houck D, Hoffman RA, Recktenwald D. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7). Proc Natl Acad Sci U S A 1995;92: 537-41.
98. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997;90:2863-92.
99. Ciudad J, San Miguel JF, Lopez-Berges MC, Vidriales B, Valverde B, Ocqueteau M, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998;16:3774-81.
100. Simpson SJ, Vachula M, Kennedy MJ, Kaizer H, Coon JS, Ghalie R, et al. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp Hematol 1995;23:1062-8.
101. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325:1525-33.
102. Zwicky CS, Maddocks AB, Andersen N, Gribben JG. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 1996;88:3314-22.
103. Tamagawa E, Ueda M, Takahashi S, Sugano K, Uematsu S, Mukai M, et al. Pancreatic lymph nodal and plexus micrometastases detected by enriched polymerase chain reaction and nonradioisotopic single-strand conformation polymorphism analysis: a new predictive factor for recurrent pancreatic carcinoma. Clin Cancer Res 1997;3:2143-9.
104. Hardingham JE, Kotasek D, Sage RE, Eaton MC, Pascoe VH, Dobrovic A. Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Mol Med 1995;1:789-94.
105. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993;53:2472-4.
106. Dietmaier W, Hartmann A, Wallinger S, Heinmoller E, Kerner T, Endl E, et al. Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol 1999;154:83-95.
107. Inoue S, Nakao A, Kasai Y, Harada A, Nonami T, Takagi H. Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/restriction fragment length polymorphism analysis. Jpn J Cancer Res 1995;86:626-30.
108. Czegledy J, Iosif C, Hansson BG, Evander M, Gergely L, Wadell G. Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer? Int J Cancer 1995;64:211-5.
109. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
110. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983;51:2116-20.
111. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987;23:707-12.
112. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-22.
113. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996;2:1035-7.
114. Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996;2:1033-5.
115. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
116. Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996;14:1868-76.
117. Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B, Selby P. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. Br J Cancer 1995;71:278-81.
118. Gunn J, McCall JL, Yun K, Wright PA. Detection of micrometastases in colorectal cancer patients by K19 and K20 reverse-transcription polymerase chain reaction. Lab Invest 1996;75:611-6.
119. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol 1996;148:649-56.
120. Schoenfeld A, Luqmani Y, Sinnett HD, Shousha S, Coombes RC. Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients. Br J Cancer 1996;74:1639-42.
121. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994; 12:725-9.
122. Hildebrandt M, Mapara MY, Korner IJ, Bargou RC, Moldenhauer G, Dorken B. Reverse transcriptase-polymerase chain reaction (RT-PCR)-controlled immunomagnetic purging of breast cancer cells using the magnetic cell separation (MACS) system: a sensitive method for monitoring purging efficiency. Exp Hematol 1997;25:57-65.
123. Mapara MY, Korner IJ, Hildebrandt M, Bargou R, Krahl D, Reichardt P, et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997;89:337-44.
124. Hoon DS, Sarantou T, Doi F, Chi DD, Kuo C, Conrad AJ, et al. Detection of metastatic breast cancer by beta-hCG polymerase chain reaction. Int J Cancer 1996;69:369-74.
125. Matsumura M, Niwa Y, Kato N, Komatsu Y, Shiina S, Kawabe T, et al. Detection of alpha-fetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma. Hepatology 1994;20:1418-25.
126. Ko Y, Klinz M, Totzke G, Gouni-Berthold I, Sachinidis A, Vetter H. Limitations of the reverse transcription-polymerase chain reaction method for the detection of carcinoembryonic antigen-positive tumor cells in peripheral blood. Clin Cancer Res 1998;4:2141-6.
127. Smith MR, Biggar S, Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 1995;55:2640-4.
128. Henke W, Jung M, Jung K, Lein M, Schlechte H, Berndt C, et al. Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int J Cancer 1997;70:52-6.
129. de Graaf H, Maelandsmo GM, Ruud P, Forus A, Oyjord T, Fodstad O, et al. Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein gene EGP-2. Int J Cancer 1997;72:191-6.
130. Traystman MD, Cochran GT, Hake SJ, Kuszynski CA, Mann SL, Murphy BJ, et al. Comparison of molecular cytokeratin 19 reverse transcriptase polymerase chain reaction (CK19 RT-PCR) and immunocytochemical detection of micrometastatic breast cancer cells in hematopoietic harvests. J Hematother 1997;6:551-61.
131. Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 1995;159:43-7.
132. Jung R, Kruger W, Hosch S, Holweg M, Kroger N, Gutensohn K, et al. Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br J Cancer 1998;78:1194-8.
133. Ferrari AC, Stone NN, Eyler JN, Gao M, Mandeli J, Unger P, et al. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 1997;89: 1498-504.
134. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995;13:2109-16.
135. Sarantou T, Chi DD, Garrison DA, Conrad AJ, Schmid P, Morton DL, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997;57:1371-6.
136. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, et al. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 1997;89:1044-9.
137. Maehara Y, Hasuda S, Abe T, Oki E, Kakeji Y, Ohno S, et al. Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. Clin Cancer Res 1998;4:2129-34.
138. Choy A, McCulloch P. Induction of tumour cell shedding into effluent venous blood breast cancer surgery. Br J Cancer 1996;73:79-82.
139. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995;346:1334-5.
140. Maehara Y, Yamamoto M, Oda S, Baba H, Kusumoto T, Ohno S, et al. Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer. Br J Cancer 1996;73:83-7.
141. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995;1:1035-9.
142. Allgayer H, Heiss MM, Riesenberg R, Grutzner KU, Tarabichi A, Babic R, et al. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 1997;57:1394-9.
143. Stephens RW, Brunner N, Janicke F, Schmitt M. The Urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998;52:99-111.
144. Brandt B, Roetger A, Heidl S, Jackisch C, Lelle RJ, Assmann G, et al. Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer 1998;76:824-8.
145. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
146. Scott AM, Welt S. Antibody-based immunological therapies. Curr Opin Immunol 1997;9:717-22.
147. Schlimok G, Funke I, Bock B, Schweiberer B, Witte J, Riethmuller G. Epithelial tumor cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterization, and prognostic significance. J Clin Oncol 1990;8:831-7.
148. Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991; 51:4712-5.
149. Pardoll DM. Cancer vaccines. Immunol Today 1993;14:310-6.
150. Muller P, Weckermann D, Riethmuller G, Schlimok G. Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet 1996;88:8-16.
151. Litle VR, Lockett SJ, Pallavicini MG. Genotype/phenotype analyses of low frequency tumor cells using computerize image microscopy. Cytometry 1996;23:344-9.
152. Forus A, Hoifodt HK, Overli GE, Myklebost O, Fodstad O. Sensitive method for FISH characterisation of breast cancer cells in bone marrow aspirates. Mol Pathol 1999;52:68-74.
153. Pantel K, Dickmanns A, Zippelius A, Klein C, Shi J, Hoechtlen-Vollmar W, et al. Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 1995;87:1162-8.
154. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997;3:505-9.
155. Rye PD, Norum L, Olsen DR, Garman-Vik S, Kaul S, Fodstad O. Brain metastasis model in athymic nude mice using a novel MUC1-secreting human breast-cancer cell line, MA11. Int J Cancer 1996;68:682-7.
156. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 1999; 59:241-8.
157. Connors TA. Is there a future for cancer chemotherapy? The Michel Clavel Lecture. Ann Oncol 1996;7:445-52.
158. van Triest B, van Groeningen CJ, Pinedo HM. Current chemotherapeutic possibilities in the treatment of colorectal cancer. Eur J Cancer 1995;31A: 1193-7.
159. Haller DG. An overview of adjuvant therapy for colorectal cancer. Eur J Cancer 1995;31A:1255-63.
160. Monson J, Pazdur R. Adjuvant therapy for colorectal cancer. Inpharma 1996;Suppl 4:3-11.
161. Schabel FM Jr. Rationale for adjuvant chemotherapy. Cancer 1977;39(6 Suppl):2875-82.
162. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
163. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50(3 Suppl): 814s-819s.
164. Ragnhammar P, Fagerberg J, Frodin JE, Hjelm AL, Lindemalm C, Magnusson I, et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced. Int J Cancer 1993;53:751-8.
165. McNeil C. A new generation of monoclonal antibodies arrives at the clinic [news]. J Natl Cancer Inst 1995;87:1658-60.
166. Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: magic bullets or misguided missiles? Immunol Today 1993;14:252-9.
167. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996;2:350-3.
168. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.
169. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63.
170. Hermanek P. What's new in TNM? Path Res Pract 1994;190:97-102.
171. Schutze K, Lahr G. Identification of expressed genes by laser-mediated manipulation of single cells. Nat Biotechnol 1998;16:737-42.
172. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmuller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A 1999; 96:4494-9.
173. Schlimok G, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmuller G. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer 1995;31A: 1799-803.
174. Pantel K, Enzmann T, Kollermann J, Caprano J, Riethmuller G, Kollermann MW. Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer 1997;71:521-5.
175. Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J, et al. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 1991;27:1461-5.
176. Thorban S, Roder JD, Pantel K, Siewert JR. Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining. Eur J Cancer 1996;32A:363-5.
177. Pantel K, von Knebel Doeberitz M, Izbicki JR, Riethmuller G. Disseminated tumor cells: diagnosis, prognostic relevance, phenotyping and therapeutic strategies. Chirurg 1997;68:1241-50
178. Brakenhoff RH, Stroomer J, De Bree R, Ten Brink CB, Weima S, Snow GB, et al. Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction. Clin Cancer Res 1999;5:725-32.
179. Braun S, Pantel K Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat 1998;52:201-16.
180. Pantel K, Braun S, Passlick B, Schlimok G. Minimal residual epithelial cancer: diagnostic approaches and prognostic relevance. Prog Histochem Cytochem 1996;30:1-60.